Compare

Benitec Biopharma Inc./$BNTC

1D1W1M3M6MYTD1Y5YMAX

About Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
Ticker
$BNTC
Sector
Health
Primary listing
NASDAQ
Employees
24
Headquarters
Hayward, United States
Website
benitec.com

BNTC Metrics

BasicAdvanced
$333M
-
-$0.98
0.27
-

What the Analysts think about BNTC

Analyst ratings (Buy, Hold, Sell) for Benitec Biopharma Inc. stock.
Analyst projections of the future price of Benitec Biopharma Inc. stock.

Bulls say / Bears say

Interim results are encouraging: all nine treated patients met the study’s response criteria, low-dose improvements persisted through 12 months, and no serious adverse events have been reported. This is an early, small study, but it supports the potential of BB-301 to improve swallowing function. (Benitec Biopharma, NeurologyLive)
BB-301 targets a serious unmet need: there are no approved OPMD therapies, and the treatment is designed as a one-time gene therapy. FDA Fast Track and orphan-drug designations could also support its development and, if approved, its commercial positioning. (Benitec Biopharma, Benitec Biopharma)
Benitec reported $180 million in cash at 30 June 2026, providing resources to advance BB-301 towards its planned pivotal trial. The company expects enrolment to start in mid-2027, giving investors a defined development milestone to watch. (Benitec Biopharma, Benitec Biopharma)
The efficacy signal rests on only nine patients in an open-label early-stage study, with just three in the high-dose cohort. The company did not report raw patient counts, confidence intervals or p-values for the dose comparisons, so the apparent benefit needs validation in larger studies. (NeurologyLive)
The pivotal-study plan is not yet final: the FDA requested additional data, including from Benitec’s natural-history study, before the design can be confirmed. Although the company still targets a mid-2027 start, further regulatory feedback could change the timetable or trial requirements. (Benitec Biopharma)
Benitec has no product revenue and reported a $45.5 million net loss for fiscal 2026; it says it will need further financing to develop and commercialise its candidates. That creates a risk of future share dilution, particularly if pivotal development costs exceed current resources. (Benitec Biopharma, Benitec Biopharma)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.

BNTC Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

BNTC Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing BNTC

Funds
Fund name
Fund size
$BNTC weighting
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.00%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.